Ambrx Biopharma Inc. (AMAM)
NYSE: AMAM
· Real-Time Price · USD
28.00
0.02 (0.07%)
At close: Mar 06, 2024, 10:00 PM
Ambrx Biopharma Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Cash & Equivalents | 225.26M | 228.26M | 149.58M | 55.61M | 55.61M | 65.64M | 170.06M | 167.2M |
Short-Term Investments | n/a | 6.82M | 7.94M | 28.87M | 28.87M | 45.25M | n/a | n/a |
Long-Term Investments | n/a | n/a | 8.8M | 16.79M | 16.79M | 18.83M | n/a | n/a |
Other Long-Term Assets | 336K | 357K | 380K | 339K | -56.05M | 466K | 530K | 402K |
Receivables | 2.36M | 2.31M | 2.32M | 2.05M | 376K | 2.24M | 1.34M | 888K |
Inventory | 5.39M | 3.03M | 2.86M | 3.73M | n/a | 6.89M | 5.17M | 4.68M |
Other Current Assets | 805K | 981K | 238K | 319K | 5.72M | 986K | 230K | 261K |
Total Current Assets | 233.82M | 241.41M | 162.94M | 90.58M | 90.58M | 121.01M | 176.81M | 173.03M |
Property-Plant & Equipment | 12.57M | 13.24M | 13.4M | 14.01M | 14.01M | 15.01M | 15.72M | 2.96M |
Goodwill & Intangibles | 24.78M | 24.93M | 25.09M | 25.25M | 25.25M | 25.57M | 35.96M | 37.34M |
Total Long-Term Assets | 37.68M | 38.53M | 47.67M | 56.39M | 56.05M | 59.86M | 52.21M | 40.7M |
Total Assets | 271.5M | 279.94M | 210.61M | 146.98M | 146.98M | 180.87M | 229.02M | 213.72M |
Account Payables | 5.14M | 6.36M | 7.11M | 3.21M | 3.21M | 5.7M | 5.27M | 3.77M |
Deferred Revenue | 407K | 407K | 407K | 407K | n/a | 3.14M | 4.27M | 4.31M |
Short-Term Debt | 1.92M | 1.85M | 1.79M | 1.73M | n/a | 1.32M | 915K | 1.67M |
Other Current Liabilities | 10.8M | 9.56M | 6.78M | 11.31M | 13.46M | 15.59M | 14.13M | 7.73M |
Total Current Liabilities | 18.27M | 18.18M | 16.09M | 16.66M | 16.66M | 25.74M | 24.58M | 17.48M |
Long-Term Debt | 8.61M | 9.16M | 9.71M | 10.24M | n/a | 11.25M | 12.21M | 740K |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 67K |
Total Long-Term Liabilities | 10.83M | 11.38M | 11.93M | 12.47M | n/a | 13.24M | 14.47M | 3.44M |
Total Liabilities | 29.1M | 29.56M | 28.02M | 29.13M | 29.13M | 38.98M | 39.05M | 20.93M |
Total Debt | 10.52M | 11.02M | 11.5M | 11.98M | n/a | 12.57M | 13.13M | 2.41M |
Common Stock | 6K | 43K | 39K | 27K | 27K | 27K | 27K | 24K |
Retained Earnings | -347.75M | -324.76M | -306.93M | -291.63M | -291.63M | -265.12M | -213.63M | -174.56M |
Comprehensive Income | -790K | -953K | -976K | -1.3M | n/a | -1.01M | -790K | -790K |
Shareholders Equity | 242.4M | 250.38M | 182.59M | 117.85M | 117.85M | 141.89M | 189.97M | 192.8M |
Total Investments | n/a | 6.82M | 7.94M | 45.67M | 45.67M | 64.08M | n/a | n/a |